Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1992-10-8
|
pubmed:abstractText |
We have evaluated the synergistic effects of interleukin-1 (IL-1) and interleukin-2 (IL-2) on the induction of lymphokine-activated killer (LAK) activity. Subcutaneous injection of recombinant IL-1 beta at an initial dose of 1 x 10(4) U was given to nine patients (five with renal cell carcinoma, two with bladder carcinoma, one with renal pelvic tumor, one with testicular tumor) on days 1 and 2 weekly for 4 weeks. The dose was increased weekly up to 4 x 10(4) U, if it was well tolerated. Peripheral blood mononuclear cells (PBMC) were isolated from patients on day 3 in the 2nd and 4th weeks, and LAK activity of PBMC against Daudi cells was measured using a 4-h 51Cr-release assay at an effector:target cell ratio of 20:1, after incubation with 50 U/ml of recombinant IL-2 for 72 h. Proliferation of PBMC was measured by tritiated thymidine incorporation after incubation with IL-2 for 72 h. IL-2 receptor (IL-2R)-positive cells in PBMC were enumerated using monoclonal antibody and flow cytometry. Mean values of LAK activity induced by IL-2 were significantly augmented after administration of IL-1 beta (p less than 0.01). IL-1 beta, however, did not enhance proliferation of PBMC caused by IL-2, nor did it increase the number of IL-2R-positive cells in peripheral blood lymphocytes of the patients. Results suggest that combination of IL-1 and IL-2 has synergistic antitumor activity in treatment of malignant diseases.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Immunologic Factors,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-1,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-2,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-6,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Interleukin-2,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins
|
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
1053-8550
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
11
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
191-7
|
pubmed:dateRevised |
2008-3-18
|
pubmed:meshHeading |
pubmed-meshheading:1515424-Cell Division,
pubmed-meshheading:1515424-Cytotoxicity Tests, Immunologic,
pubmed-meshheading:1515424-Humans,
pubmed-meshheading:1515424-Immunologic Factors,
pubmed-meshheading:1515424-Interleukin-1,
pubmed-meshheading:1515424-Interleukin-2,
pubmed-meshheading:1515424-Interleukin-6,
pubmed-meshheading:1515424-Killer Cells, Lymphokine-Activated,
pubmed-meshheading:1515424-Leukocytes, Mononuclear,
pubmed-meshheading:1515424-Receptors, Interleukin-2,
pubmed-meshheading:1515424-Recombinant Proteins,
pubmed-meshheading:1515424-Urologic Neoplasms
|
pubmed:year |
1992
|
pubmed:articleTitle |
Enhancement of lymphokine-activated killer activity induction in vitro by interleukin-1 administered in patients with urological malignancies.
|
pubmed:affiliation |
Department of Urology, School of Medicine, Keio University, Tokyo, Japan.
|
pubmed:publicationType |
Journal Article
|